No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
J.P. Morgan's Top Healthcare Stocks for 2025
Express News | PTC Therapeutics Inc: PTC's Fourth Approval Application Submitted to FDA in 2024
Express News | PTC Therapeutics Announces Vatiquinone Nda Submission to FDA for the Treatment of Children and Adults Living With Friedreich Ataxia
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living With Friedreich Ataxia
Express News | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)